This study was designed to investigate the influence of TSER and MTHFR polymorphisms on the clinical outcomes of patients with colorectal cancer receiving 5-FU-based chemotherapy.
Introduction
Despite advancements in the diagnosis and early treatment of colorectal cancer, the need for better tools to predict outcome and response to treatment is well recognized. Pharmacogenetics has attracted considerable attention in the study of cancer chemotherapy treatment in recent years. 5 -FU has been used in the treatment of cancers such as colorectal cancer, breast cancer and head and neck cancer for about 50 years. The major target of 5-FU is thymidylate synthase (TS), which catalyzes the transformation dUMP into dTMP, an important process in DNA synthesis and repair.
However, objective tumor responses are observed in only 15% to 20% of patients treated with 5-FU. 1 One current strategy to improve the effectiveness of chemotherapy for the treatment of advanced colorectal cancer is based on the ability of reducing folate to modulate the cytotoxic effect of 5-FU. Experimental studies have established that optimal TS inhibition requires the stabilization of ternary complex between TSER, fluorodeoxyuridinemonophosphate (FdUMP) converted from 5-FU, and 5,10-methylenetetrahydrofolate (CH 2 FH 4 ). 2, 3 Accordingly, clinical studies have demonstrated that higher chemotherapy efficacy of 5-FU is associated with folic acid, a precursor of 5,10-methylenetetrahydrofolate. 4, 5 Methylenetetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylenetetrahydrofolate (5,10-CH 2 FH 4 ) to 5'-methyltetrahydrofolate (5-CH 3 FH 4 ). MTHFR plays a central role in folate metabolism, regulating the flow of folate between these two important pathways: production of thymidylate and purines for DNA synthesis and supply of methyl groups for the synthesis of methionine and DNA methylation. 6 Two common polymorphisms of the MTHFR gene have been described, and the 677C>T polymorphism has been reported to affect enzymatic activity. 7 In vitro analysis of MTHFR activity indicates that the MTHFR 677T allele variant has an enzymatic activity of 30% compared with the MTHFR 677CC genotype.
Decreased enzymatic activity of MTHFR in MTHFR 677TT homozygotes may lead to accumulation of 5,10-methylenetetrahydrofolate and thereby improve the efficacy of 5'-FU treatment through stabilization of the ternary complex. 8 We hypothesized that the variable number of tandem repeat (VNTR) of the TSER gene together with MTHFR 677C>T polymorphism could alter drug activity and predict drug toxicity or efficacy.
In this study, we investigated the associations between two common polymorphisms and prognosis in 103 colorectal cancer patients receiving 5-FU chemotherapy. We also evaluated whether combined genotypes of the MTHFR 677C>T and TSER polymorphisms affect colorectal cancer patient survival.
Results

TSER and MTHFR genotype distribution
We examined the TSER and MTHFR 677C>T polymorphisms in 35 consecutive patients with proximal colorectal cancer and 68 consecutive patients with distal colorectal cancer. The clinical and pathological features of the colorectal cancer treated by surgery and adjuvant chemotherapy are shown in Table 1 
Prognostic significance of TSER and MTHFR genotypes
We investigated the associations of the TSER and MTHFR genotypes with prognosis. The TSER and the MTHFR genotypes were each stratified into two groups because the statistical power was insufficient for analysis with more than two genotype groups. The TSER functional groups were classified as 2R(-) (3R3R) and 2R(+) (2R3R and 2R2R). The MTHFR 677C>T genotypes were classified as 677CC vs. 677CT and 677TT.
There were no significant relationships between overall prognosis and the genotype groups when all patients were included in the analysis (Figs. 1a and 1b) . Thus, the prognostic significance of the combined genotypes was further evaluated (Fig. 1c) . The combined genotypes were classified into low-risk type (having two or less risk alleles) and high-risk type (having three or more risk alleles): low-risk type (3R3R+ 677CC, 2R3R+677CC, 2R2R+677CC, 2R3R+677CT, 2R2R+677CT, 2R2R+677TT), high-risk type (3R3R+677CT, 3R3R+677TT, 2R3R+677TT). There was a significant correlation with prognosis in the combined TSER and MTHFR 677C>T genotypes (P=0.028).
When we analyzed survival according to the colorectal cancer sub-site, there was also a significant difference between proximal colon and distal colon cancers (P=0.002) (Fig. 2a) .
However, in patients with proximal colon or distal colon cancers, the difference in survival rates between combined TSER and MTHFR 677C>T genotypes did not reach statistical significance (proximal colon P=0.558, Fig. 2b ; distal colon P=0.058, Fig. 2c ).
Discussion
Gene polymorphisms could be an important predictive factor in the treatment of colorectal cancer with fluoropyrimidine-based chemotherapy. Several studies have suggested that TSER polymorphisms influence 5-FU sensitivity in vitro and in vivo. The human TS promoter gene is polymorphic with either double-or triple-tandem repeats of a 28-bp sequence downstream of the cap site in the 5'-terminal regulatory region. 9 In vitro studies have shown that the TSER gene with triple-tandem repeats has 2.6-times higher activity than that with double-tandem repeats. 14 TS level in tumor tissue may also be important because high expression of the TS protein and TSER mRNA has been associated with resistance to 5-FU-based treatment, leading to poor survival outcomes in colorectal cancer. [11] [12] [13] Pullarkat et al. 14 reported that patients with the 2R2R TSER polymorphism had a higher response rate than patients with 2R3R and 3R3R. Also, the 3R3R TSER gene polymorphism was associated with worse prognosis in colorectal cancer patients receiving 5-FU-based chemotherapy than 2R2R and 2R3R, 15 ; however, differing results have also been reported. 16 Other data have suggested that the MTHFR 677C>T polymorphism is also important for the effect of 5-FU-based chemotherapy. Decreased activity in MTHFR 677T allele carriers increases the availability of 5,10-methylene THF, which is a cofactor for 5-fluorouracil inhibition of TS. An in vitro study by Sohn KJ et al. 17 suggested that cells expressing the mutant 677T MTHFR had decreased MTHFR activity, thermolability, and increased thymidylate synthase activity compared with cells expressing the wild-type MTHFR. The MTHFR 677T mutation also exhibited increased chemosensitivity of colon and breast cancers to 5-FU. In a large case-control study nested within a multiethnic cohort, they found an inverse association of the MTHFR 677TT genotype with risk of colorectal cancer. The MTHFR 677T allele had 23% reduced risk of colorectal cancer. 18 In this study, we did not observe a significant effect of the TSER and the MTHFR 677C>T polymorphisms on the survival rate of colorectal cancer patients receiving 5-FU chemotherapy.
Also, we did not find a significant relationship of each polymorphism and prognosis according to pathologic stage (data not shown).
The TSER 2R(+) variants appeared to have better prognosis than TSER 2R(-) variants, but there was no significant difference in the pathologic stage. However, we observed a significant correlation with prognosis in combined TSER and MTHFR 677C>T genotypes. High-risk type was associated with worse prognosis of colorectal cancer receiving 5-FU-based chemotherapy.
Mutation of important genes such as TSER and MTHFR does not have good effects on survival and inhibition of tumorigenesis even if the MTHFR 677T allele has a synergistic effect on 5-FUbased therapy.
We hypothesized that the chemotherapy effect would differ according to the tumor location in colorectal cancer. Colorectal cancers are divided according to the location of the cancer, such as the proximal and distal colon. Several studies provide evidence that epigenetic mechanisms such as gene methylation play a differential role in proximal versus distal colon carcinogenesis.
Proximal colon cancer has been associated with hypermethylation of genes involved in mismatch repair, such as hMLH1, or in cell cycle control, such as p16 INK4 and p14. Conversely, distal colon cancers have been associated with chromosomal instability by hypomethylation.
Thus, the tumorigenesis mechanism differs according to the tumor location in colorectal cancer; therefore, we believe that the treatment methods of these cancers should also be different.
Wolmark et al. 19 determined the prognostic significance of tumor location and showed that tumor location was a strong prognostic determinant and that lesions located in the distal colon showed better survival than those in the proximal colon. Several other studies have also suggested that patients with distal colon cancer exhibit better survival rates than those with proximal colon cancer. 20, 21 However, these studies included cohorts that did not undergo chemotherapy treatment.
However, our results were opposite to this. When we analyzed survival according to the tumor location of colorectal cancers, proximal colon cancers had significantly better prognosis than distal colon cancers.
Elsaleh et al. 22 also reported that the presence of microsatellite instability in the proximal colon carcinoma group was associated with significantly improved prognosis and may also increase the likelihood of survival after chemotherapy. The main cause of proximal cancer associated with hypermethylation was frequent methylation of CpG islands in the promoter regions of repair genes. Whether this is associated with good response to chemotherapy in vivo because of deficiencies in DNA repair or because it is linked to the methylator phenotype remains unclear. Indeed, the methylator phenotype might prove to be an even stronger predictive factor for the response of colorectal cancers to chemotherapy. 23, 24 In the present study, we found that proximal colon cancer patients had a better prognosis than distal colon cancer patients through 5-FU chemotherapy. We also found that high-risk type was associated with worse prognosis of colorectal cancer receiving 5-FU-based chemotherapy. In conclusion, we suggest that chemotherapeutic treatment of colorectal cancer must differ according to the location of tumorigenesis and the combined genotypes of MTHFR and TSER.
Patients and Methods
Patients and DNA isolation
We enrolled 103 colorectal cancer (CLC) patients (mean age±SD, 58.58±14. Table 1 ). All patients completed scheduled postoperative adjuvant chemotherapy. Specimens were taken from frozen or paraffin-embedded tissues by phenol/chloroform extraction methods and the quality was adequate. Paraffin was removed with xylene at 50 overnight and the products were treated with 10% SDS and proteinase K.
Genotyping of the VNTR in the thymidylate synthase enhancer region
TSER 28-bp tandem repeat number was investigated by PCR using forward primer 5'-GTG GCT CCT GCG TTT CCC CC-3' and reverse primer 5'-GCT CCG AGC CGG CCA CAG GCA TGG CGC GG-3' as described previously. 25 PCR was performed using the PCR premix kit (HotStart PCR Premix, Bioneer, Korea) in a 20 l volume, and 0.5 mol of each primer was used.
Amplified fragments were confirmed on a 3% agarose gel by electrophoresis. TSER 2R or 3R polymorphism was genotyped according to the size of the amplified fragment: 2R corresponded to 220 bp and 3R corresponded to 248 bp.
Genotyping of the MTHFR 677C>T
The MTHFR genotype was examined using the PCR-RFLP method. DNA fragment containing MTHFR 677C>T (Ala to Val) was amplified with a GeneAmp PCR machine (Perkin Elmer 2400), forward primer, 5'-TGA AGG AGA AGG TGT CTG CGG GA-3' and reverse primer, 5'-AGG ACG GTG CGG TGA GAG TG.-3'. MTHFR 677C>T genotypes were identified as described in Kim et al. 26 
Statistical analyses
Categorical data were analyzed using Chi-square and ANOVA tests. Significance was set at the 0.05 level. Survival curves were generated using the Kaplan-Meier method. 27 The log-rank statistic was used to compare survival distributions. 28 All calculations were done with GraphPad 
